Amazon shares ‘a coiled spring' going into Q4 report: UBS

UBS raised its 12-month price target on Amazon to $311 (from $310) and reiterated a Buy, calling shares a "coiled spring" as AWS momentum accelerates into Q4 2025. UBS materially lifted multi-year capex forecasts — aggregated Q4 2025–Q4 2027 capex to $344B (from $300B) and AWS spending to $260B (from $225B) — as Amazon plans to double capacity by 2027; UBS projects a doubling of AWS revenue by 2028 could add roughly $20B of incremental free cash flow that year. Street consensus expects Q4 revenue of $211.56B (+12.7% YoY) and EPS $1.98 (vs. $1.86 prior year); UBS also flagged upside from faster GMV, one-day/same-day Prime expansion, improved e-commerce margins and ad/Prime Video monetization.

Analysis

Market structure: AWS acceleration and UBS's doubled-capacity thesis favor Amazon (AMZN), GPU/AI infrastructure suppliers (NVDA, AMD, INTC) and data-center REITs (EQIX, QTS) while increasing competitive pressure on legacy retailers (WMT, TGT) and smaller cloud providers. Higher capex ($344B aggregated through Q4 2027 per UBS) signals durable demand for servers, power and networking, tightening semiconductor/GPU supply and lifting input-cost trajectories for energy and copper in 2026–28. Cross-asset: a re-rate into growth should compress AMZN equity volatility post-earnings, modestly steepen tech credit spreads if capex is debt-financed, and strengthen USD if tech outperformance attracts inflows.

Risk assessment: Tail risks include US/EU antitrust action within 12–24 months, large AWS outage or GPU supply shock, and misallocated capex that depresses 2026–27 FCF by >$10–20B relative to UBS’s base. Near-term (days) earnings execution and guidance will drive moves; short-term (weeks–months) sentiment shifts on AWS growth trajectory; long-term (2026–28) payoff depends on AWS monetizing AI demand and achieving >2x revenue by 2028. Hidden dependencies: NVDA supply, power costs, and enterprise AI adoption cycles; catalysts include Q4 print, FY26 capex guidance, and major hyperscaler enterprise AI contracts announced in next 90 days.

Trade implications: Favor directional long AMZN exposure into the print with size discipline (2–4% portfolio) and convex optionality (LEAP calls) to capture upside to UBS’s $311 12‑month TP while limiting downside. Consider relative-value trades long AMZN / short WMT to express e-commerce share gains over 3–12 months, and overweight NVDA (or semiconductor suppliers) for 6–24 month secular GPU tailwinds. Avoid financing long-dated AMZN exposure with short-dated naked puts; prefer spread structures around earnings to control Vega.

Contrarian angles: Consensus understates near-term FCF pressure from materially raised capex (incremental $44B to AWS capex through 2027 per UBS) — upside to revenue may lag free cash flow realization, creating a 6–18 month re-rating risk. The market may be underpricing execution risk on same-day grocery rollouts and overpricing seamless AWS margin expansion given GPU cost inflation. Historical parallel: Amazon’s prior capex cycles (2012–16) preceded strong long-term returns but included multi-year FCF troughs; if capex delivers slower revenue conversion this cycle, upside is delayed and valuations vulnerable.

Key Decisions for Investors

• Establish a 2.5% long position in AMZN at or below $240 with a 12‑month price target of $311 (UBS TP) and a hard stop-loss at $200 (≈−16.7%) to limit drawdown if AWS guidance disappoints on the Q4 print.
• Buy limited-size LEAP calls: AMZN Jan 19, 2027 300C representing ~1% portfolio notional (cost-limited exposure to upside from AWS re-acceleration); if premium >2.5% of position, convert to a 300C/360C debit call spread to cap cost.
• Implement a pair trade: long AMZN (2% portfolio) / short WMT (1.5% portfolio) for 3–12 months to express e-commerce share gains from same‑day/Prime grocery; close or trim if AMZN outperforms by >20% or WMT outperforms by >10%.
• Overweight NVDA by +3–5% (or buy NVDA 6–12 month calls) to capture GPU supply tightness; if NVDA announces material production shortfall or ASP decline within 90 days, reduce exposure by 50%.